Tenascin-C and integrins in cancer

Cell Adhesion and Migration

Volumn 9, Issue 1-2, 2015, Pages 96-104

  Yoshida, Toshimichi ^a,b   Akatsuka, Tatsuya ^a   Imanaka Yoshida, Kyoko ^a,b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

Cancer cell; Integrins; Splice variant; Stromal cell; Tenascin C

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBRONECTIN; INTEGRIN; INTEGRIN RECEPTOR; PROTEIN TYROSINE PHOSPHATASE; SYNDECAN 4; TENASCIN; TOLL LIKE RECEPTOR 4;

ANGIOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SIGNALING ASSAY; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MYOFIBROBLAST; NEOPLASM; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; STROMA CELL; TISSUE REPAIR; TNC GENE; TUMOR GROWTH; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; CELL ADHESION; CELL PROLIFERATION; HUMANS; INTEGRINS; NEOPLASMS; PROTEIN SPLICING; TENASCIN;

EID: 84948747425     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.1080/19336918.2015.1008332     Document Type: Review

References (94)

1. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244:143-63; http://dx.doi.org/10.1016/j.canlet.2006.02.017
2. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci 2011; 68:3175-99; http://dx.doi.org/10.1007/s00018-011-0783-6
3. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-87; http://dx.doi.org/10.1016/S0092-8674(02)00971-6
4. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006; 119:3901-3; http://dx.doi.org/10.1242/jcs.03098
5. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009; 122:159-63; http://dx.doi.org/10.1242/jcs.018093
6. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 2002; 4:E83-90; http://dx.doi.org/10.1038/ncb0402-e83
7. Ganguly KK, Pal S, Moulik S, Chatterjee A. Integrins and metastasis. Cell Adh Migr 2013; 7:251-61; http://dx.doi.org/10.4161/cam.23840
8. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 1994; 126:539-48;; http://dx.doi.org/10.1083/jcb.126.2.539
9. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7:883-92
10. Adamsky K, Schilling J, Garwood J, Faissner A, Peles E. Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase b (RPTPbeta) to tenascin C. Oncogene 2001; 20:609-18; http://dx.doi.org/10.1038/sj.onc.1204119
11. Milev P, Fischer D, Häring M, Schulthess T, Margolis RK, Chiquet-Ehrismann R, Margolis RU. The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatase-zeta/b. J Biol Chem 1997; 272:15501-9; http://dx.doi.org/10.1074/jbc.272.24.15501
12. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001; 154:459-68; http://dx.doi.org/10.1083/jcb.200103103
13. Fischer D, Chiquet-Ehrismann R, Bernasconi C, Chiquet M. A single heparin binding region within the fibrinogen-like domain is functional in chick tenascin-C. J Biol Chem 1995; 270:3378-84; http://dx.doi.org/10.1074/jbc.270.27.16315
14. Weber P, Zimmermann DR, Winterhalter KH, Vaughan L. Tenascin-C binds heparin by its fibronectin type III domain five. J Biol Chem 1995; 270: 4619-23; http://dx.doi.org/10.1074/jbc.270.9.4619
15. Saito Y, Imazeki H, Miura S, Yoshimura T, Okutsu H, Harada Y, Ohwaki T, Nagao O, Kamiya S, Hayashi R, et al. A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem 2007; 282:34929-37; http://dx.doi.org/10.1074/jbc.M705608200
16. Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009; 10:645-52; http://dx.doi.org/10.2174/138945009788680374
17. Yokosaki Y, Monis H, Chen J, Sheppard D. Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the b subunit extracellular and cytoplasmic domains. J Biol Chem 1996; 271:24144-50; http://dx.doi.org/10.1074/jbc.271.39.24144
18. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115:339-47; http://dx.doi.org/10.1172/JCI200523183
19. Katoh D, Nagaharu K, Shimojo N, Hanamura N, Yamashita M, Kozuka Y, Imanaka-Yoshida K, Yoshida T. Binding of avb1 and avb6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis 2013; 2:e65; http://dx.doi.org/10.1038/oncsis.2013.27
20. Ramos DM, Dang D, Sadler S. The role of the integrin a v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res 2009; 29: 125-30
21. Sheppard D. Integrin-mediated activation of latent transforming growth factor b. Cancer Metastasis Rev 2005; 24:395-402; http://dx.doi.org/10.1007/s10555-005-5131-6
22. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: Direct and synergistic effects with transforming growth factor b 1. Int J Cancer 2003; 105:53-60; http://dx.doi.org/10.1002/ijc.11037
23. Høye AM, Couchman JR, Wewer UM, Fukami K, Yoneda A. The newcomer in the integrin family: integrin a9 in biology and cancer. Adv Biol Regul 2012; 52:326-39; http://dx.doi.org/10.1016/j.jbior.2012.03.004
24. Yokosaki Y, Matsuura N, Higashiyama S, Murakami I, Obara M, Yamakido M, Shigeto N, Chen J, Sheppard D. Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. J Biol Chem 1998; 273:11423-8; http://dx.doi.org/10.1074/jbc.273.19.11423
25. Gulubova M, Vlaykova T. Immunohistochemical assessment of fibronectin and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases. Acta Histochem 2006; 108:25-35; http://dx.doi.org/10.1016/j.acthis.2005.12.001
26. Allen MD, Vaziri R, Green M, Chelala C, Brentnall AR, Dreger S, Vallath S, Nitch-Smith H, Hayward J, Carpenter R, et al. Clinical and functional significance of a9b1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 2011; 223: 646-58; http://dx.doi.org/10.1002/path.2833
27. Ota D, Kanayama M, Matsui Y, Ito K, Maeda N, Kutomi G, Hirata K, Torigoe T, Sato N, Takaoka A, et al. Tumor-a9b1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts. J Mol Med (Berl) 2014; 92(12):1271-81
28. Ou J, Peng Y, Deng J, Miao H, Zhou J, Zha L, Zhou R, Yu L, Shi H, Liang H. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition. Carcinogenesis 2014; 35:1661-70
29. Häkkinen L, Hildebrand HC, Berndt A, Kosmehl H, Larjava H. Immunolocalization of tenascin-C, alpha9 integrin subunit, and alphavbeta6 integrin during wound healing in human oral mucosa. J Histochem Cytochem 2000; 48:985-98; http://dx.doi.org/10.1177/002215540004800712
30. Yoshimura E, Majima A, Sakakura Y, Sakakura T, Yoshida T. Expression of tenascin-C and the integrin a 9 subunit in regeneration of rat nasal mucosa after chemical injury: involvement in migration and proliferation of epithelial cells. Histochem Cell Biol 1999; 111:259-64; http://dx.doi.org/10.1007/s004180050356
31. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-5; http://dx.doi.org/10.1038/sj.bjc.6601576
32. Weis SM, Cheresh DA. aV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 2011; 1: a006478; http://dx.doi.org/10.1101/cshperspect.a006478
33. Prieto AL, Edelman GM, Crossin KL. Multiple integrins mediate cell attachment to cytotactin/tenascin. Proc Natl Acad Sci U S A 1993; 90:10154-8; http://dx.doi.org/10.1073/pnas.90.21.10154
34. Yokoyama K, Erickson HP, Ikeda Y, Takada Y. Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin a vbeta 3. J Biol Chem 2000; 275:16891-8; http://dx.doi.org/10.1074/jbc.M000610200
35. Ishigaki T, Imanaka-Yoshida K, Shimojo N, Matsushima S, Taki W, Yoshida T. Tenascin-C Enhances Crosstalk Signaling of Integrin a v b 3/PDGFR-b Complex by SRC Recruitment Promoting PDGFInduced Proliferation and Migration in Smooth Muscle Cells. J Cell Physiol 2011; 226:2617-24; http://dx.doi.org/10.1002/jcp.22614
36. Li E, Brown SL, Stupack DG, Puente XS, Cheresh DA, Nemerow GR. Integrin a(v)beta1 is an adenovirus coreceptor. J Virol 2001; 75:5405-9; http://dx.doi.org/10.1128/JVI.75.11.5405-5409.2001
37. Mercurio AM. Lessons from the alpha2 integrin knockout mouse. Am J Pathol 2002; 161:3-6; http://dx.doi.org/10.1016/S0002-9440(10)64149-1
38. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 1996; 109 (Pt 3):643-52
39. Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by a 2 b 1 and a v b 3 integrins. J Cell Sci 1993; 105 (Pt 4):1001-12
40. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. Collagen I-mediated upregulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol 2008; 180:1277-89; http://dx.doi.org/10.1083/jcb.200708137
41. Stipp CS. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 2010; 12:e3; http://dx.doi.org/10.1017/S1462399409001355
42. Mercado ML, Nur-e-Kamal A, Liu HY, Gross SR, Movahed R, Meiners S. Neurite outgrowth by the alternatively spliced region of human tenascin-C is mediated by neuronal alpha7beta1 integrin. J Neurosci 2004; 24:238-47; http://dx.doi.org/10.1523/JNEUROSCI.4519-03.2004
43. Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN, Nelson J, Michalopoulos GK, Luo JH. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 2007; 99:868-80; http://dx.doi.org/10.1093/jnci/djk199
44. Hartner A, Dötsch J. Lessons in congenital and acquired renal disease from alpha8 integrin mutant mice. Pediatr Nephrol 2002; 17:882-8; http://dx.doi.org/10.1007/s00467-002-0950-y
45. Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D, Pytela R. The human integrin a 8 b 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J Biol Chem 1995; 270:23196-202; http://dx.doi.org/10.1074/jbc.270.39.23196
46. Denda S, Müller U, Crossin KL, Erickson HP, Reichardt LF. Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin a 8 b 1 receptor interactions with tenascin: murine a 8 b 1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C. Biochemistry 1998; 37:5464-74; http://dx.doi.org/10.1021/bi9727489
47. Scherberich A, Tucker RP, Degen M, Brown-Luedi M, Andres AC, Chiquet-Ehrismann R. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-a induced expression in vitro. Oncogene 2005; 24:1525-32; http://dx.doi.org/10.1038/sj.onc.1208342
48. Salmivirta M, Elenius K, Vainio S, Hofer U, Chiquet-Ehrismann R, Thesleff I, Jalkanen M. Syndecan from embryonic tooth mesenchyme binds tenascin. J Biol Chem 1991; 266:7733-9
49. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001; 61:8586-94
50. Orend G, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R. Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 2003; 22:3917-26; http://dx.doi.org/10.1038/sj.onc.1206618
51. Midwood KS, Valenick LV, Hsia HC, Schwarzbauer JE. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell 2004; 15:5670-7; http://dx.doi.org/10.1091/mbc.E04-08-0759
52. Tanaka R, Seki Y, Saito Y, Kamiya S, Fujita M, Okutsu H, Iyoda T, Takai T, Owaki T, Yajima H, et al. Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin a5b1. J Biol Chem 2014; 289:17699-708; http://dx.doi.org/10.1074/jbc.M113.546622
53. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62:3289-97
54. Yoshida T, Matsumoto EI, Hanamura N, Kalembeyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 1997; 182:421-8; http://dx.doi.org/10.1002/(SICI)1096-9896(199708)182:4%3c421::AID-PATH886%3e3.0.CO;2-U
55. Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995; 1:1035-41
56. Kalembeyi I, Yoshida T, Iriyama K, Sakakura T. Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: an in situ hybridization study. Int J Dev Biol 1997; 41:569-73
57. Fouda GG, Jaeger FH, Amos JD, Ho C, Kunz EL, Anasti K, Stamper LW, Liebl BE, Barbas KH, Ohashi T, et al. Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. Proc Natl Acad Sci U S A 2013; 110:18220-5; http://dx.doi.org/10.1073/pnas.1307336110
58. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 1997; 73:10-5; http://dx.doi.org/10.1002/(SICI)1097-0215(19970926)73:1% 3c10::AID-IJC2%3e3.0.CO;2-4
59. Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L, Kosmehl H. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004; 203:771-9; http://dx.doi.org/10.1002/path.1589
60. Metwaly H, Maruyama S, Yamazaki M, Tsuneki M, Abe T, Jen KY, Cheng J, Saku T. Parenchymal-stromal switching for extracellular matrix production on invasion of oral squamous cell carcinoma. Hum Pathol 2012; 43:1973-81; http://dx.doi.org/10.1016/j.humpath.2012.02.006
61. Hindermann W, Berndt A, Borsi L, Luo XM, Hyckel P, Katenkamp D, Kosmehl H. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999; 189:475-80; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4%3c475:: AID-PATH462%3e3.0.CO;2-V
62. Herold-Mende C, Andl T, Laemmler F, Reisser C, Eichhorn S. Expression and localization profile of tenascin in squamous cell carcinomas of the head and neck. H 1999; 47:723-9
63. Yoshida T, Yoshimura E, Numata H, Sakakura Y, Sakakura T. Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells. Virchows Arch 1999; 435:496-500; http://dx.doi.org/10.1007/s004280050433
64. Pollanen R, Soini Y, Vuopala S, Laara E, Lehto VP. Tenascin in human papillomavirus associated lesions of the uterine cervix. J Clin Pathol 1996; 49:521-3; http://dx.doi.org/10.1136/jcp.49.6.521
65. Latijnhouwers M, Bergers M, Ponec M, Dijkman H, Andriessen M, Schalkwijk J. Human epidermal keratinocytes are a source of tenascin-C during wound healing. J Invest Dermatol 1997; 108:776-83; http://dx.doi.org/10.1111/1523-1747.ep12292170
66. Aukhil I, Sahlberg C, Thesleff I. Basal layer of epithelium expresses tenascin mRNA during healing of incisional skin wounds. J Periodontal Res 1996; 31:105-12; http://dx.doi.org/10.1111/j.1600-0765.1996.tb00471.x
67. Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-b in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 1989; 49:4322-5
68. Martinez-Outschoorn U, Pavlides S, Whitaker-Menezes D, Daumer K, Milliman J, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010; 9:2423-33; http://dx.doi.org/10.4161/cc.9.12.12048
69. Hiraiwa N, Kida H, Sakakura T, Kusakabe M. Induction of tenascin in cancer-cells by interactions with embryonic mesenchyme mediated by a diffusible factor. J Cell Sci 1993; 104:289-96
70. Zagzag D, Friedlander DR, Dosik J, Chikramane S, Chan W, Greco MA, Allen JC, Dorovini-Zis K, Grumet M, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996; 56:182-9
71. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992; 52:688-92; http://dx.doi.org/10.1002/ijc.2910520504
72. Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. Amer J Pathol 2003; 162:1857-67; http://dx.doi.org/10.1016/S0002-9440(10)64320-9
73. Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, et al. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006; 132:537-46; http://dx.doi.org/10.1007/s00432-006-0106-8
74. Latijnhouwers MA, de Jongh GJ, Bergers M, de Rooij MJ, Schalkwijk J. Expression of tenascin-C splice variants by human skin cells. Arch Dermatol Res 2000; 292:446-54; http://dx.doi.org/10.1007/s004030000152
75. Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC. Expression of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci 1998; 39:1135-42
76. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Amer J Pathol 2005; 167:71-80.
77. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001; 92:1419-26
78. Paron I, Berchtold S, Vörös J, Shamarla M, Erkan M, Höfler H, Esposito I. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One 2011; 6:e21684
79. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-c isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995; 270:8650-4
80. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, Shimizu K, Miura K, Fukuchi Y. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005; 25:489-95
81. Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, Shinozuka N, Saeki T, Okazaki Y, Koyama I. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer. World J Surg 2007; 31:388-94
82. Gecks T, Junker K, Franz M, Richter P, Walther M, Voigt A, Neri D, Kosmehl H, Wunderlich H, Kiehntopf M, et al. B domain containing Tenascin-C: A new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder? Clin Chim Acta 2011; 412:1931-6
83. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90
84. Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, Ogawa T, Shiraishi T, Imanaka-Yoshida K. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 2011; 178:754-63
85. Alcaraz LB, Exposito JY, Chuvin N, Pommier RM, Cluzel C, Martel S, Sentis S, Bartholin L, Lethias C, Valcourt U. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-b. J Cell Biol 2014; 205:409-28
86. Castellon R, Caballero S, Hamdi HK, Atilano SR, Aoki AM, Tarnuzzer RW, Kenney MC, Grant MB, Ljubimov AV. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci 2002; 43:2758-66
87. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 2001; 107:785-90
88. Ziu M, Schmidt NO, Cargioli TG, Aboody KS, Black PM, Carroll RS. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 2006; 79:125-33
89. Nakahara H, Gabazza EC, Fujimoto H, Nishii Y, D’Alessandro-Gabazza CN, Bruno NE, Takagi T, Hayashi T, Maruyama J, Maruyama K, et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 2006; 36:3334-45
90. El-Karef A, Yoshida T, Gabazza EC, Nishioka T, Inada H, Sakakura T, Imanaka-Yoshida K. Deficiency of tenascin-C attenuates liver fibrosis in immunemediated chronic hepatitis in mice. J Pathol 2007; 211:86-94
91. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, et al. Tenascin-C is an endogenous activator of Tolllike receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15:774-80; http://dx.doi.org/10.1038/nm.1987
92. Rudnick JA, Kuperwasser C. Stromal biomarkers in breast cancer development and progression. Clin Exp Metastasis 2012; 29:663-72; http://dx.doi.org/10.1007/s10585-012-9499-8
93. O’Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, et al. VEGF-A and Tenascin-C produced by S100A4C stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A 2011; 108:16002-7; http://dx.doi.org/10.1073/pnas.1109493108
94. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17:867-74; http://dx.doi.org/10.1038/nm.2379